Polycythemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} {{AE}}{{Debduti}} | {{CMG}} {{AE}}{{Debduti}}{{ZO}} | ||
*Medicines that may be used include:<ref name="pmid31151982">{{cite journal| author=Spivak JL| title=How I treat polycythemia vera. | journal=Blood | year= 2019 | volume= 134 | issue= 4 | pages= 341-352 | pmid=31151982 | doi=10.1182/blood.2018834044 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31151982 }} </ref> | *Medicines that may be used include:<ref name="pmid31151982">{{cite journal| author=Spivak JL| title=How I treat polycythemia vera. | journal=Blood | year= 2019 | volume= 134 | issue= 4 | pages= 341-352 | pmid=31151982 | doi=10.1182/blood.2018834044 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31151982 }} </ref> | ||
| Line 11: | Line 10: | ||
*'''[[Interferon]]''': reduce [[blood cell]] counts. [[Peg interferon]] can be used to reduce established [[splenomegaly]] but not to normal size. | *'''[[Interferon]]''': reduce [[blood cell]] counts. [[Peg interferon]] can be used to reduce established [[splenomegaly]] but not to normal size. | ||
*'''[[Anagrelide]]''': used to treat [[thrombocytosis]]. | *'''[[Anagrelide]]''': used to treat [[thrombocytosis]]. | ||
*'''[[Ruxolitinib]] ([[JAK1/2 inhibitor]])''': it used when patients are [[intolerant]] or unresponsive to [[hydroxyurea]] | *'''[[Ruxolitinib]] ([[JAK1/2 inhibitor]])''': it used when patients are [[intolerant]] or unresponsive to [[hydroxyurea]] proved to be effective in PPMF and chronic-phase PV; provided a durable relief in symptoms, blood count control, significant reduction in splenomegaly, and better survival based on COMFORT trials.<ref name="pmid22375970">{{cite journal| author=Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V | display-authors=etal| title=JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. | journal=N Engl J Med | year= 2012 | volume= 366 | issue= 9 | pages= 787-98 | pmid=22375970 | doi=10.1056/NEJMoa1110556 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22375970 }} </ref> | ||
*'''[[Aspirin]]''': indicated at low dose to prevent [[thrombosis]], when there is [[insufficient]] control of [[microvascular]] [[symptoms]] or other [[cardiovascular]] risk factors exist. | |||
*'''Aspirin''': indicated at low dose to prevent thrombosis, when there is insufficient control of microvascular symptoms or other cardiovascular risk factors exist. | *'''[[Hypouricemic]] Agents ([[Allopurinol]] and [[febuxostat]])''': required if there is significant [[hyperuricemia]]. | ||
*'''Hypouricemic Agents (Allopurinol and febuxostat)''': required if there is significant hyperuricemia. | |||
*Management of pruritus: '''antihistamines''' and '''selective serotonin reuptake inhibitors (SSRIs)''' are usually used to relief the symptoms, '''narrow band ultraviolet-B phototherapy''' can also be used to treat pruritus.<ref name="pmid15897170">{{cite journal| author=Madkan VK, Bandow GD, Koo JY| title=Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy. | journal=J Dermatolog Treat | year= 2005 | volume= 16 | issue= 1 | pages= 56-7 | pmid=15897170 | doi=10.1080/09546630410024529 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15897170 }} </ref> | *Management of pruritus: '''antihistamines''' and '''selective serotonin reuptake inhibitors (SSRIs)''' are usually used to relief the symptoms, '''narrow band ultraviolet-B phototherapy''' can also be used to treat pruritus.<ref name="pmid15897170">{{cite journal| author=Madkan VK, Bandow GD, Koo JY| title=Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy. | journal=J Dermatolog Treat | year= 2005 | volume= 16 | issue= 1 | pages= 56-7 | pmid=15897170 | doi=10.1080/09546630410024529 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15897170 }} </ref> | ||
Latest revision as of 18:24, 24 January 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Polycythemia medical therapy |
|
Risk calculators and risk factors for Polycythemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]Zaida Obeidat, M.D.
- Medicines that may be used include:[1]
- Hydroxyurea: it considered as a second-line therapy, it showed lower rates of thrombosis compared to phlebotomy alone based on a study by the PVSG.
Indications for use include poor venous access, high phlebotomy requirement, when phlebotomy is contraindicated or not possible, severe thrombocytosis, and unmanageable pruritus.
- Interferon: reduce blood cell counts. Peg interferon can be used to reduce established splenomegaly but not to normal size.
- Anagrelide: used to treat thrombocytosis.
- Ruxolitinib (JAK1/2 inhibitor): it used when patients are intolerant or unresponsive to hydroxyurea proved to be effective in PPMF and chronic-phase PV; provided a durable relief in symptoms, blood count control, significant reduction in splenomegaly, and better survival based on COMFORT trials.[2]
- Aspirin: indicated at low dose to prevent thrombosis, when there is insufficient control of microvascular symptoms or other cardiovascular risk factors exist.
- Hypouricemic Agents (Allopurinol and febuxostat): required if there is significant hyperuricemia.
- Management of pruritus: antihistamines and selective serotonin reuptake inhibitors (SSRIs) are usually used to relief the symptoms, narrow band ultraviolet-B phototherapy can also be used to treat pruritus.[3]
Sumptomatic Treatment in Polycythemia Vera[4]
| Symptoms | Treatment |
|---|---|
| Pruritus | H1 and H2 blocking antihistamines (diphenhydramine [Benadryl], cyproheptadine [Periactin], hydroxyzine [Atarax, Vistaril], fexofenadine [Allegra], terfenadine [Seldane]) Paroxetine (Paxil) Oatmeal or starch baths (in lukewarm water) Recombinant interferon alfa-2b (intronA) |
| Erythromelalgia | Aspirin, 50 to 100 mg daily Myelosuppressive agents |
Myelosuppressive Agents for the Treatment of Polycythemia Vera[4]
| Agent | Class | Common side effects | Uncommon side effects | Percautions |
|---|---|---|---|---|
| Hydroxyurea (Hydrea) | Antimetabolite | Anemia, neutropenia, oral ulcers, skin ulcers, hyperpigmentation, nail changes | Leg ulcers, nausea, diarrhea, fever, elevated liver function test results | Renal disease |
| Recombinant interferon alfa-2b (Intron A) | Myelosuppressive | Influenza-like symptoms, fatigue, anorexia, weight loss, alopecia, headache, nausea, insomnia, body pain | Confusion, depression, autoimmunity, hyperlipidemia | Psychiatric disease, cardiovascular disease |
| Radioactive phosphorus | Radiopharmaceutica | Anemia, thrombocytopenia, leukopenia, Leukemia may develop after treatment | Diarrhea, fever, nausea, emesis | — |
| Busulfan (Myleran) | Alkylating agent | Pancytopenia, hyperpigmentation, ovarian suppression | Pulmonary fibrosis, leukemia, seizure, hepatic veno-occlusion | Seizure disorder |
References
- ↑ Spivak JL (2019). "How I treat polycythemia vera". Blood. 134 (4): 341–352. doi:10.1182/blood.2018834044. PMID 31151982.
- ↑ Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V; et al. (2012). "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis". N Engl J Med. 366 (9): 787–98. doi:10.1056/NEJMoa1110556. PMID 22375970.
- ↑ Madkan VK, Bandow GD, Koo JY (2005). "Resolution of pruritus secondary to polycythemia vera in a patient treated with narrow-band ultraviolet B phototherapy". J Dermatolog Treat. 16 (1): 56–7. doi:10.1080/09546630410024529. PMID 15897170.
- ↑ 4.0 4.1 Stuart BJ, Viera AJ (2004). "Polycythemia vera". Am Fam Physician. 69 (9): 2139–44. PMID 15152961.